GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (OTCPK:WUXIF) » Definitions » EV-to-Revenue

Wuxi AppTec Co (Wuxi AppTec Co) EV-to-Revenue : 2.68 (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Wuxi AppTec Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Wuxi AppTec Co's enterprise value is $15,178 Mil. Wuxi AppTec Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $5,659 Mil. Therefore, Wuxi AppTec Co's EV-to-Revenue for today is 2.68.

The historical rank and industry rank for Wuxi AppTec Co's EV-to-Revenue or its related term are showing as below:

WUXIF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.93   Med: 11.73   Max: 26.58
Current: 2.73

During the past 10 years, the highest EV-to-Revenue of Wuxi AppTec Co was 26.58. The lowest was 2.93. And the median was 11.73.

WUXIF's EV-to-Revenue is ranked better than
53.3% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.02 vs WUXIF: 2.73

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-28), Wuxi AppTec Co's stock price is $4.3501. Wuxi AppTec Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.91. Therefore, Wuxi AppTec Co's PS Ratio for today is 2.28.


Wuxi AppTec Co EV-to-Revenue Historical Data

The historical data trend for Wuxi AppTec Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co EV-to-Revenue Chart

Wuxi AppTec Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.73 19.27 15.12 6.05 5.17

Wuxi AppTec Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.05 5.82 4.48 6.17 5.17

Competitive Comparison of Wuxi AppTec Co's EV-to-Revenue

For the Diagnostics & Research subindustry, Wuxi AppTec Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuxi AppTec Co's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Wuxi AppTec Co's EV-to-Revenue falls into.



Wuxi AppTec Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Wuxi AppTec Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=15178.385/5658.834
=2.68

Wuxi AppTec Co's current Enterprise Value is $15,178 Mil.
Wuxi AppTec Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,659 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co  (OTCPK:WUXIF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Wuxi AppTec Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.3501/1.906
=2.28

Wuxi AppTec Co's share price for today is $4.3501.
Wuxi AppTec Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.91.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co (Wuxi AppTec Co) Business Description

Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.